The agreement enables Reliance Life Sciences to springboard into the US market using Medicure's commercial reach.
Medicure said it has entered an agreement with Reliance Life Sciences (RLS) to market an unnamed cardiovascular biosimilar. Medicure, a Canadian company based in Winnipeg, Alberta, referred to the biosimilar candidate only as “the product.”
As yet, RLS, based in Navi Mumbai, India, has no FDA biosimilar approvals for the US market.
RLS is a diverse pharmaceuticals company with a focus on biotherapeutics, including biosimilars, regenerative medicine, pharmaceuticals, clinical research services, and molecular medicine.
Building Up Medicure's Cardiovascular Portfolio
The agreement gives Medicure exclusive rights to market the agent in the United States, Canada, and the European Union.
"We are very pleased with the agreement we have reached with RLS. The product fits well with Medicure's mission of being a significant cardiovascular company focused on the US market," Albert Friesen, CEO of Medicure, said in a statement.
According to a 2018 analysis by IQVIA, RLS had 14 biosimilars in its pipeline, making it one of the leading biosimilar developers at the time. The Medicure statement described RLS as a company with $86 billion in annual revenues.
Medicure specializes in the development and commercialization of cardiovascular therapies. Two of the products in its portfolio are tirofiban hydrochloride (Aggrastat), an anticoagulant, and pitavastatin (Zypitamag), a cholesterol-lowering statin. Both of these products are marketed in the United States.
No further details of the biosimilar agreement or marketing plan were provided.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Interchangeability Labels and Expanded Biosimilar Partnerships
May 29th 2025The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple sclerosis, while 2 other companies expand their biosimilar partnership to include more products.